Ginette Dubuc

Title: **Innovative Contributions of Ginette Dubuc in the Field of Antibody Fragments**

Introduction

Ginette Dubuc is a notable inventor based in Ottawa, Canada, who has made significant contributions to the field of biotechnology. With a unique focus on antibody technology, she has been instrumental in advancing the understanding and application of antigen-binding antibody fragments derived from llama antibodies. Her work not only showcases her inventive spirit but also emphasizes the potential of her discoveries in various medical and research applications.

Latest Patents

Ginette Dubuc holds a patent for "Single-domain antigen-binding antibody fragments derived from llama antibodies." This patent discloses a phage display library of variable heavy domain (VH or VHH) fragments, known as sdAb fragments, derived from the antibody repertoire of a non-immunized llama. These sdAb fragments are particularly noteworthy due to their design, characterized by the absence of cysteine residues in the complementarity determining regions (CDRs) and a very low presence of residues such as glutamic acid, arginine, and glycine at specific positions of the variable heavy domain. The vast size of this library, on the order of 10, serves as a source of high-affinity antigen-binding fragments, making it a valuable tool for research applications. The library is preferably generated using a modified fd-tet phage, which grows in plaques without the presence of tetracycline.

Career Highlights

Ginette Dubuc is associated with the National Research Council of Canada, where she continues to push the boundaries of scientific inquiry. Her innovative approach to developing antibody fragments positions her as a key figure in the field of biotechnology and immunology. With a keen interest in utilizing non-immunized llama antibodies, she has demonstrated a commitment to finding new solutions within the realm of antibody engineering.

Collaborations

Throughout her career, Ginette has collaborated with prominent colleagues including Jamshid Tanha and Saran A Narang. These partnerships have facilitated an exchange of ideas and expertise, further enhancing the research and development process within her innovative projects. Their collective efforts have fostered an environment conducive to producing groundbreaking results in biotechnological research.

Conclusion

In summary, Ginette Dubuc's contributions to the field of antibody technology, particularly through her patent for single-domain antibody fragments, highlight her status as an influential inventor in Canada. Her ongoing work at the National Research Council of Canada, along with her collaborative efforts, continues to pave the way for advancements in biotechnology and therapeutic applications. Ginette's achievements serve as an inspiration to aspiring inventors and scientists aiming to transform their ideas into impactful realities.